Vertex Pharmaceuticals Incorporated — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparisons are with Q1 2022 unless noted. Vertex is a global biotechnology company focused on specialty medicines. Its principal commercial business is cystic fibrosis (CF), with additional clinical programs across several disease areas.
Key financial results
- Revenue: Net product revenue was $2.375 billion, up 13% from $2.098 billion. TRIKAFTA/KAFTRIO revenue rose 19% to $2.097 billion; U.S. revenue grew 3% and ex-U.S. revenue grew 33%.
- Profit and margins: Operating income was $779.0 million, down 25%; net income was $699.8 million, down 8%. Diluted EPS was $2.69 versus $2.96. Operating margin was approximately 32.8% (about 49.6% in Q1 2022); net margin was approximately 29.5% (about 36.3%). Cost of sales was 11% of revenue versus 12%.
- Expenses: Total costs and expenses increased 51% to $1.596 billion. R&D rose 24% to $742.6 million, and acquired in-process R&D (AIPR&D) was $347.1 million versus $2.0 million, primarily reflecting upfront payments to Entrada and CRISPR.
- Cash flow: Operating cash flow was $899.9 million versus $956.2 million. Investing cash outflow was $1.834 billion, primarily due to purchases of marketable securities; financing cash outflow was $294.7 million, including share repurchases and employee tax-withholding payments.
- Liquidity and debt: Cash, cash equivalents and marketable securities totaled $11.496 billion at March 31, up 6% from year-end. Working capital was $9.940 billion. The $500 million revolving credit facility was undrawn; the company reported compliance with its covenants. Balance-sheet obligations include finance and operating leases.
Material changes and business developments
- Revenue growth was driven by TRIKAFTA/KAFTRIO uptake, particularly in international markets; revenue from older CF products declined primarily as patients switched to the triple combination.
- Interest income increased to $122.6 million from $1.6 million, mainly reflecting higher market rates and greater invested balances. Other income was $1.3 million versus an expense of $72.8 million, largely reflecting changes in fair value of strategic equity investments.
- Vertex recorded $225.1 million of upfront AIPR&D expense for Entrada and $100.0 million for a CRISPR gene-editing license; it also invested $24.9 million in Entrada equity.
- The company authorized up to $3.0 billion in share repurchases and repurchased 459,017 shares for $135.6 million during the quarter. $2.9 billion remained authorized at quarter-end.
Outlook, commentary and risks
- Management expects existing cash, investments and product-sale cash flows to fund operations for at least the next 12 months. The filing provides no specific full-year revenue or earnings guidance.
- Near-term development and regulatory priorities include exa-cel for sickle cell disease and transfusion-dependent beta thalassemia; management reported completed U.S. rolling submissions and prior E.U. and U.K. submissions. Timing and approvals remain uncertain.
- Management expected pivotal studies of once-daily vanzacaftor combination therapy and the VX-548 acute-pain program to complete by late 2023 or early 2024. Development timelines are forward-looking and may change.
- Key risks include clinical and regulatory uncertainty, reimbursement and market access, manufacturing and supply-chain demands (particularly for cell and gene therapies), and volatility in strategic equity investment values. The filing reported no material legal proceedings, no material changes to previously disclosed risk factors, and no material contingent liabilities accrued beyond contingent consideration.
Important facts for investors to verify
- Whether TRIKAFTA/KAFTRIO growth and international reimbursement access continue to offset declines in older CF products.
- Regulatory decisions and launch timing for exa-cel, and clinical progress for VX-548 and vanzacaftor combination therapy.
- How recurring R&D investment and variable AIPR&D payments affect operating profitability and cash generation.
- Future capital allocation, including use of the remaining share-repurchase authorization and potential milestone or royalty commitments.